News & Events about Karuna Therapeutics Inc.
Karuna Therapeutics, Inc. (NASDAQ:KRTX Get Rating) Director James Healy sold 6,027 shares of Karuna Therapeutics stock in a transaction that occurred on Friday, January 13th. The shares were sold at an average price of $199.90, for a total value of $1,204,797.30. Following the completion of ...
Karuna Therapeutics, Inc. (NASDAQ:KRTX Get Rating) insider Stephen K. Brannan sold 5,000 shares of the stock in a transaction on Monday, January 9th. The stock was sold at an average price of $197.52, for a total transaction of $987,600.00. Following the completion of the sale, the insider now owns ...
NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Karuna Therapeutics, Inc. (NASDAQ: KRTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-...
Karuna Therapeutics, Inc. (NASDAQ:KRTX Get Rating) insider Stephen K. Brannan sold 5,000 shares of the firms stock in a transaction dated Friday, December 9th. The stock was sold at an average price of $200.76, for a total transaction of $1,003,800.00. Following the sale, the insider now owns 15,000...
Karuna Therapeutics, Inc. (NASDAQ:KRTX Get Rating) COO Andrew Craig Miller sold 15,000 shares of the companys stock in a transaction dated Thursday, December 1st. The stock was sold at an average price of $228.30, for a total transaction of $3,424,500.00. Following the completion of ...